BLUE BELL, Pa.--(BUSINESS WIRE)--Locus Pharmaceuticals, Inc. (Locus) announced today the appointment of Jamie Freedman, M.D., Ph.D. as President and CEO of Locus. He will succeed H. Joseph Reiser, Ph.D., who is retiring but will remain on the Board of Directors.
Dr. Freedman joined Locus in January, 2008 as Chief Medical Officer, and Vice President of Clinical Research and Regulatory Affairs. According to Dr. Reiser, “In a short period, Dr. Freedman has been instrumental in setting the strategies for the Locus development programs. Dr. Freedman’s experience in oncology and broader drug development will be critical to the success of Locus’ early pipeline. We are highly confident in Dr. Freedman’s ability to create exceptional value at Locus.”
Prior to joining Locus, Dr. Freedman was at Merck Research Labs for five years where he held a variety of positions of increasing responsibility within clinical research. Dr. Freedman received M.D. and Ph.D. degrees from Tufts University, and trained in Medicine and Hematology-Oncology at University of California, San Francisco and Harvard, respectively. His research focused on the structure and function of proteins involved in blood coagulation and cancer. He also held a staff position in the Department of Medicine at the University of Pennsylvania until the end of 2006.
Brendan O’Leary, Ph.D. of Prism VentureWorks and Chairman of the Board for Locus said, “We are very pleased to have realized a strong internally derived leadership change for Locus. This is a tribute to the experienced team that Dr. Reiser built at the Company, and we are appreciative for his leadership and commitment over the years.”
Dr. Freedman commented, “I am honored to have the opportunity to lead Locus. Locus is a very special biotech company with unique molecules derived from its leading computational technology. Our strong focus in cancer and inflammation could provide new treatment opportunities for patients with such high unmet needs.”
About Locus Pharmaceuticals
Locus Pharmaceuticals, Inc. (privately held) has a proprietary computational drug design technology, and is using it to create a pipeline of highly competitive drug development candidates, including direct and allosteric kinase inhibitors for cancer and inflammation. Locus has entered into various technology and drug design/development collaborations with pharmaceutical partners. Visit www.locuspharma.com for more information.
Contacts
Locus Pharmaceuticals, Inc. Jamie Freedman, M.D., Ph.D. President and Chief Executive Officer 215-358-2001 Locus Pharmaceuticals, Inc.
